Suven Life Sciences’ Pashamylaram facility near Hyderabad has undergone successful inspection by the US health regulator.
The facility has undergone renewal inspection from February 5-18 by the United States Food and Drug Administration (USFDA), Suven Life Sciences said in a filing to BSE today.
The plant is considered to be in an acceptable state of compliance with regard to current good manufacturing practices (CGMP) and the agency has issued an establishment inspection report (EIR) for the facility, it added.
So far the company has filed 19 drug master files and 5 abbreviated new drug applications. The company’s stock was trading 5.43 per cent up at Rs 191.10 on the BSE.